The European Commission has authorized the use of the Spikevax XBB.1.5-adapted COVID-19 vaccine, developed by Moderna, as a crucial weapon in the ongoing battle against the disease. This marks the third adaptation of the vaccine to address new variants of the virus.
Health and Food Safety Commission Stella Kyriakides emphasized the importance of vaccination as a key tool in combatting both COVID-19 and seasonal influenza. She encouraged individuals aged 60 and above, those with weakened immune systems, and individuals with underlying health conditions to receive their booster dose of the latest updated version of the vaccine, formulated to target the current spreading variants. Kyriakides stressed the need for continued vigilance and collective effort in protecting one another.
The European Medicines Agency (EMA) conducted a comprehensive evaluation of the Spikevax XBB.1.5-adapted vaccine through an accelerated assessment process. Based on the results of this evaluation, the European Commission expedited the authorization of the adapted vaccine to enable member states to adequately prepare for their autumn-winter vaccination campaigns.
As we enter a season where COVID-19 and seasonal influenza co-circulate, the authorization of the Spikevax XBB.1.5-adapted vaccine brings a renewed sense of hope and protection. It serves as a testament to the ongoing commitment to combatting the ever-evolving nature of the virus.
Source: European Commission and European Medicines Agency
Note: This article is based on the information provided by the European Commission and European Medicines Agency. The views and positions expressed in the article do not necessarily reflect those of EU Reporter.
Definitions:
– Spikevax XBB.1.5-adapted COVID-19 vaccine: The vaccine developed by Moderna that has been adapted to target specific variants of the COVID-19 virus.
– COVID-19: The respiratory illness caused by the novel coronavirus, SARS-CoV-2.
– European Commission: The executive branch of the European Union responsible for proposing legislation and implementing decisions.
– European Medicines Agency (EMA): The agency of the European Union that evaluates and supervises medicinal products for human and veterinary use.
